Zhang Financial LLC decreased its stake in shares of Vertex Pharmaceuticals Incorporated (NASDAQ:VRTX - Free Report) by 71.6% in the 1st quarter, according to its most recent Form 13F filing with the SEC. The fund owned 1,316 shares of the pharmaceutical company's stock after selling 3,315 shares during the period. Zhang Financial LLC's holdings in Vertex Pharmaceuticals were worth $638,000 at the end of the most recent reporting period.
A number of other large investors also recently bought and sold shares of VRTX. ABC Arbitrage SA purchased a new position in shares of Vertex Pharmaceuticals in the 4th quarter valued at $1,510,000. Highview Capital Management LLC DE raised its position in Vertex Pharmaceuticals by 1.8% in the fourth quarter. Highview Capital Management LLC DE now owns 5,771 shares of the pharmaceutical company's stock valued at $2,324,000 after purchasing an additional 102 shares during the period. Davidson Investment Advisors lifted its stake in shares of Vertex Pharmaceuticals by 26.0% during the fourth quarter. Davidson Investment Advisors now owns 61,161 shares of the pharmaceutical company's stock worth $24,630,000 after purchasing an additional 12,631 shares in the last quarter. Jones Financial Companies Lllp boosted its position in shares of Vertex Pharmaceuticals by 75.5% in the fourth quarter. Jones Financial Companies Lllp now owns 2,468 shares of the pharmaceutical company's stock worth $994,000 after buying an additional 1,062 shares during the period. Finally, New York State Common Retirement Fund grew its stake in shares of Vertex Pharmaceuticals by 0.8% in the fourth quarter. New York State Common Retirement Fund now owns 362,334 shares of the pharmaceutical company's stock valued at $145,912,000 after buying an additional 2,855 shares in the last quarter. Hedge funds and other institutional investors own 90.96% of the company's stock.
Wall Street Analyst Weigh In
Several equities analysts recently commented on VRTX shares. Erste Group Bank lowered Vertex Pharmaceuticals from a "strong-buy" rating to a "hold" rating in a research report on Friday, May 23rd. Needham & Company LLC restated a "hold" rating on shares of Vertex Pharmaceuticals in a research note on Tuesday, May 6th. Cantor Fitzgerald reaffirmed an "overweight" rating and set a $535.00 price target on shares of Vertex Pharmaceuticals in a report on Tuesday, May 6th. Bank of America boosted their price objective on shares of Vertex Pharmaceuticals from $555.00 to $567.00 and gave the stock a "buy" rating in a report on Monday, March 31st. Finally, Scotiabank lowered their target price on Vertex Pharmaceuticals from $450.00 to $442.00 and set a "sector perform" rating for the company in a research note on Tuesday, May 6th. Fourteen equities research analysts have rated the stock with a hold rating, sixteen have given a buy rating and one has assigned a strong buy rating to the stock. Based on data from MarketBeat, the company presently has a consensus rating of "Moderate Buy" and a consensus price target of $515.04.
View Our Latest Analysis on VRTX
Vertex Pharmaceuticals Stock Performance
Shares of NASDAQ:VRTX traded down $4.61 during trading hours on Friday, hitting $455.45. The stock had a trading volume of 1,021,326 shares, compared to its average volume of 1,417,847. The stock's fifty day simple moving average is $462.88 and its 200 day simple moving average is $460.24. The firm has a market capitalization of $116.96 billion, a price-to-earnings ratio of -207.02, a PEG ratio of 2.11 and a beta of 0.41. Vertex Pharmaceuticals Incorporated has a 1-year low of $377.85 and a 1-year high of $519.88. The company has a debt-to-equity ratio of 0.01, a quick ratio of 2.35 and a current ratio of 2.69.
Vertex Pharmaceuticals (NASDAQ:VRTX - Get Free Report) last posted its quarterly earnings data on Monday, May 5th. The pharmaceutical company reported $4.06 EPS for the quarter, missing analysts' consensus estimates of $4.29 by ($0.23). Vertex Pharmaceuticals had a negative net margin of 4.86% and a negative return on equity of 2.02%. The firm had revenue of $2.77 billion for the quarter, compared to analysts' expectations of $2.85 billion. During the same period in the prior year, the company posted $4.76 earnings per share. Vertex Pharmaceuticals's quarterly revenue was up 2.6% compared to the same quarter last year. Sell-side analysts anticipate that Vertex Pharmaceuticals Incorporated will post 15.63 earnings per share for the current fiscal year.
About Vertex Pharmaceuticals
(
Free Report)
Vertex Pharmaceuticals Incorporated, a biotechnology company, engages in developing and commercializing therapies for treating cystic fibrosis (CF). It markets TRIKAFTA/KAFTRIO for people with CF with at least one F508del mutation for 2 years of age or older; SYMDEKO/SYMKEVI for people with CF for 6 years of age or older; ORKAMBI for CF patients 1 year or older; and KALYDECO for the treatment of patients with 1 year or older who have CF with ivacaftor.
See Also
Before you consider Vertex Pharmaceuticals, you'll want to hear this.
MarketBeat keeps track of Wall Street's top-rated and best performing research analysts and the stocks they recommend to their clients on a daily basis. MarketBeat has identified the five stocks that top analysts are quietly whispering to their clients to buy now before the broader market catches on... and Vertex Pharmaceuticals wasn't on the list.
While Vertex Pharmaceuticals currently has a Moderate Buy rating among analysts, top-rated analysts believe these five stocks are better buys.
View The Five Stocks Here
If a company's CEO, COO, and CFO were all selling shares of their stock, would you want to know? MarketBeat just compiled its list of the twelve stocks that corporate insiders are abandoning. Complete the form below to see which companies made the list.
Get This Free Report
Like this article? Share it with a colleague.
Link copied to clipboard.
